News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. Oxford Finance Provides $10 Million Senior Debt Facility to Oxford Bio

Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics26/01/2017 Alexandria & San Jose, USA and Oxford, UK – Oxford Finance LLC, an industry-leading specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $10 million senior secured term loan with Oxford BioTherapeutics (“OBT”), an international, clinical-stage biotechnology company focused on develop


2. Contractor appointed for £13 million landmark Oxford scheme

Contractor appointed for £13 million landmark Oxford scheme08/02/2017The Oxford Science Park has awarded a £13 million design and build contract for Plot 12, a new state of the art office building, capable of housing laboratories, and with roof terrace, comprising 61,500 sq ft (5,713 sq m), to Barnwood Construction Ltd.Gloucestershire-based Barnwood Construction has delivered commercial office and laboratory projects for many clients across southern and central England including: MEPC,


3. NIHR Brain Injury Healthcare Technology Co-operative – Seedcorn Fundin

NIHR Brain Injury Healthcare Technology Co-operative – Seedcorn Funding Competition 2016/2017 – FUNDING CALL ROUND 2 NOW OPEN13/02/2017The NIHR Brain Injury Healthcare Technology Co-operative is pleased to announce the second round of its second national competition. The seed funding call (up to £10,000) is for the early development of novel technology-based solutions applicable to the brain injury pathway, from prevention of injury all the way through to technologies for indepe


4. Cell Lines & Media for Difficult to Culture Tumor Types

Cell Lines & Media for Difficult to Culture Tumor Types23/02/2017AMSBIO has introduced a new range of cancer cell line models and culture media for the most difficult to culture tumor types where no models may exist.Alex Sim, Managing Director at AMSBIO said, “Our new partnership with Cellaria Biosciences expands our existing portfolio by introducing patient-derived cancer models; allowing customers to conduct research and drug discovery initiatives to advance precision


5. Oxford Immunotec Reports Fourth Quarter and Full Year 2016 Financial R

Oxford Immunotec Reports Fourth Quarter and Full Year 2016 Financial Results27/02/2017Oxford, UK & Marlborough, USA – Oxford Immunotec Global PLC, a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced fourth quarter and full year 2016 financial results.“We are very pleased with our performance during the fourth quarter and throughout 2016, as we evolved f



Page 20 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2019